Advertisement

Table of Contents

Masters of Immunology

Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities

Milestones in Cancer Immunology

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Spontaneous Peripheral T-cell Responses toward the Tumor-Associated Antigen Cyclin D1 in Patients with Clear Cell Renal Cell Carcinoma
    Stefanie R. Dannenmann, Thomas Hermanns, Ali Bransi, Claudia Matter, Lotta von Boehmer, Stefan Stevanovic, Peter Schraml, Holger Moch, Alexander Knuth and Maries van den Broek
    Cancer Immunol Res November 1 2013 1 (5) 288-295; DOI:10.1158/2326-6066.CIR-13-0113

    Analyzing samples from patients with primary clear cell renal cell carcinoma (ccRCC), Dannenmann and colleagues identified naturally occurring, polyfunctional Cyclin D1-specific CD8+ T cells from patients with Cyclin-D1+ tumors, and they propose to develop Cyclin D1 as a target for immunotherapy in patients with ccRCC.

Priority Briefs

  • Priority Briefs
    NY-ESO-1 Expression in Meningioma Suggests a Rationale for New Immunotherapeutic Approaches
    Gilson S. Baia, Otavia L. Caballero, Janelle S.Y. Ho, Qi Zhao, Tzeela Cohen, Zev A. Binder, Vafi Salmasi, Gary L. Gallia, Alfredo Quinones-Hinojosa, Alessandro Olivi, Henry Brem, Peter Burger, Robert L. Strausberg, Andrew J.G. Simpson, Charles G. Eberhart and Gregory J. Riggins
    Cancer Immunol Res November 1 2013 1 (5) 296-302; DOI:10.1158/2326-6066.CIR-13-0029

    Baia, Caballero, and colleagues found that NY-ESO-1 is the most frequently expressed cancer/testis antigen in meningioma tumors, and its expression positively correlates with higher-grade disease and worst prognosis. NY-ESO-1 proteins elicit spontaneous humoral immune responses; the authors propose that NY-ESO-1–based immunotherapy should be explored as a complement to standard therapy for patients with meningioma.

  • Priority Briefs
    CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg
    Maha Ayyoub, Pascale Pignon, Jean-Marc Classe, Kunle Odunsi and Danila Valmori
    Cancer Immunol Res November 1 2013 1 (5) 303-308; DOI:10.1158/2326-6066.CIR-13-0062-T

    CD4+ T effector cells specific for the tumor antigen NY-ESO-1 were found to accumulate at ovarian cancer tumor sites; they maintain an effector phenotype/function and remain distinct from Treg, even when Treg are present at high proportions. These findings encourage the use of combination therapies aiming at enhancing tumor antigen-specific immune responses and eliminating or inactivating Treg.

Research Articles

  • Research Articles
    Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy
    Samuel T. Workenhe, Jonathan G. Pol, Brian D. Lichty, Derek T. Cummings and Karen L. Mossman
    Cancer Immunol Res November 1 2013 1 (5) 309-319; DOI:10.1158/2326-6066.CIR-13-0059-T

    Workenhe and colleagues show that the combination regimen of oncolytic virus with mitoxantrone significantly increases the efficacy of either treatment alone by enhancing the immunogenicity of and breaking immune tolerance against tumor-associated antigens, an Achilles' heel of current cancer therapy.

  • Research Articles
    GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
    David A. Schaer, Sadna Budhu, Cailian Liu, Campbell Bryson, Nicole Malandro, Adam Cohen, Hong Zhong, Xia Yang, Alan N. Houghton, Taha Merghoub and Jedd D. Wolchok
    Cancer Immunol Res November 1 2013 1 (5) 320-331; DOI:10.1158/2326-6066.CIR-13-0086

    Schaer and colleagues show that GITR ligation by agonist antibody DTA-1 inhibits intratumor immune suppression by inducing tumor-dependent loss of Foxp3 and altered expression of transcription factors and cytokines important for Treg function, resulting in impaired Treg lineage stability and enhanced killing of tumor cells by T effectors. These results will inform the effective use of GITR therapy in humans.

  • Research Articles
    Peptide Vaccination in Montanide Adjuvant Induces and GM-CSF Increases CXCR3 and Cutaneous Lymphocyte Antigen Expression by Tumor Antigen–Specific CD8 T Cells
    Eleanor Clancy-Thompson, Laura K. King, Lenora D. Nunnley, Irene M. Mullins, Craig L. Slingluff Jr and David W. Mullins
    Cancer Immunol Res November 1 2013 1 (5) 332-339; DOI:10.1158/2326-6066.CIR-13-0084

    A melanoma-specific peptide vaccine in Montanide ISA-51 induces tumor-infiltrating CD8+ T cells expressing CXCR3, with a subpopulation coexpressing CLA, both of which are associated with skin homing and are increased by GM-CSF. The authors hypothesize that specific modifications of the metastatic tumor microenvironment to elicit chemoattraction of vaccine-induced T cells would enhance vaccine efficacy for disseminated metastases.

  • Research Articles
    Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
    Takemasa Tsuji, Paul Sabbatini, Achim A. Jungbluth, Erika Ritter, Linda Pan, Gerd Ritter, Luis Ferran, David Spriggs, Andres M. Salazar and Sacha Gnjatic
    Cancer Immunol Res November 1 2013 1 (5) 340-350; DOI:10.1158/2326-6066.CIR-13-0089

    In a comprehensive analysis of what contributes to the integrated immune responses elicited by the vaccination of ovarian cancer patients with OLP from tumor antigen NY-ESO-1, Tsuji and colleagues show that Montanide ISA-51 is critical for the expansion of high-avidity antigeninduced CD4+ T cells, and a TLR ligand poly-ICLC accelerates the induction and differentiation of vaccine-induced antigen-specific Th1 cells.

Back to top
Cancer Immunology Research: 1 (5)
November 2013
Volume 1, Issue 5

Sign up for alerts

Jump to

Advertisement